Vivani Medical completes dosing in SLIM-1 Phase 1 trial of NPM-139 semaglutide implant for weight management

Reuters2026/08/06 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vivani Medical completed enrollment and initial dosing in SLIM-1, a Phase 1 study of NPM-139, a long-acting semaglutide implant for chronic weight management.
Results have not been presented; top-line data from the 20-participant trial is expected in November 2026.
The trial is designed to assess safety, tolerability, and drug exposure, with a Wegovy injection group included for comparison.
The program targets less frequent dosing to support adherence, with an implant designed for reversibility if treatment must be stopped.
Management expects the Phase 1 readout to support a Phase 2 dose-ranging trial start in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vivani Medical completes dosing in SLIM-1 Phase 1 trial of NPM-139 semaglutide implant for weight management

You may also like

Crypto prices